Jyong Biotech Ltd. Ordinary Shares(MENS)Earnings, Financials & Key Ratios

MENS•NASDAQ

$2.19

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Specialty Pharma

AboutJyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stagesShow more

Revenue$0
EBITDA-$3M-29.5%
Net Income-$5M-54.7%
EPS (Diluted)-0.06-61.2%

MENS Price & Volume

Jyong Biotech Ltd. Ordinary Shares (MENS) stock price & volume — 10-year historical chart

Loading chart...

Clinical Stage Liquidity Crisis Threatens Survival

Investment Thesis • Updated 2024Q4

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Imminent liquidity and dilution

Key Thesis Takeaways

Jyong Biotech remains a high-risk, pre-revenue entity entirely dependent on the successful regulatory progression of its botanical drug candidates.
The firm faces an acute liquidity crisis, evidenced by a current ratio of 0.02 and a negative equity position of $36.5 million as of 2024Q4.
Investors should monitor the high probability of dilutive financing, as the company's $18.1 million debt burden and persistent quarterly operating losses of $553,000 necessitate immediate capital infusion to maintain operational continuity.

Verdict Logic

the company's current ratio of 0.02 and minimal cash balance of $98,000 indicate an imminent risk of insolvency or extreme shareholder dilution.

MENS Growth Metrics

Jyong Biotech Ltd. Ordinary Shares (MENS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-

Return on Capital

10 Years-40.87%

5 Years-47.12%

3 Years-

Last Year-

Latest MENS News

Recent stock market news and headlines for Jyong Biotech Ltd. Ordinary Shares (MENS)

GlobeNewsWire·5 days ago

Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention

New Taipei City, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced its participation in the BIO International Convention (BIO 2026), held in San Diego, California, from June 22 to June 25, 2026.

Peers Comparison

Key metrics vs top competitors for Jyong Biotech Ltd. Ordinary Shares (MENS)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
MENSJyong Biotech Ltd. Ordinary SharesCurrent	$2.19	$166.42M	-34.20	—	—	—	—
AEYEAudioEye, Inc.	$7.41	$92.58M	-29.64	14.52%	-9.05%	-70.95%	—
NUVBNuvation Bio Inc.	$5.67	$1.97B	-9.45	698.96%	-102.06%	-44.1%	—
HALOHalozyme Therapeutics, Inc.	$81.57	$9.68B	31.86	37.55%	23.13%	126.27%	—
NVAXNovavax, Inc.	$9.46	$1.56B	3.72	64.69%	-14.73%	—	—
OCGNOcugen, Inc.	$1.50	$507.78M	-6.52	8.83%	-1605.22%	-127987.5%	—

Compare MENS vs Peers

Jyong Biotech Ltd. Ordinary Shares (MENS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs AEYE

Most directly comparable listed peer for MENS.

Scale Benchmark

vs MEDP

Larger-name benchmark to compare MENS against a more recognizable public peer.

Peer Set

Compare Top 5

vs AEYE, NUVB, HALO, NVAX

Get notified when MENS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

MENS Frequently Asked Questions

Jyong Biotech Ltd. Ordinary Shares (MENS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Is MENS profitable?

Jyong Biotech Ltd. Ordinary Shares (MENS) reported a net loss of $0.0M for fiscal year 2025.

Dividend & Returns

What is Jyong Biotech Ltd. Ordinary Shares's free cash flow?

Jyong Biotech Ltd. Ordinary Shares (MENS) had negative free cash flow of $0.0M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in MENS back in 2020?

Total return calculator · dividends reinvested · 6+ years of data

See returns →

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

MENSJyong Biotech Ltd. Ordinary SharesCurrent

$2.19

$166.42M

-34.20

—

AEYEAudioEye, Inc.

$7.41

$92.58M

-29.64

14.52%

-9.05%

-70.95%

—

NUVBNuvation Bio Inc.

$5.67

$1.97B

-9.45

698.96%

-102.06%

-44.1%

—

HALOHalozyme Therapeutics, Inc.

$81.57

$9.68B

31.86

37.55%

23.13%

126.27%

—

NVAXNovavax, Inc.

$9.46

$1.56B

3.72

64.69%

-14.73%

—

OCGNOcugen, Inc.

$1.50

$507.78M

-6.52

8.83%

-1605.22%

-127987.5%

—